Lipid Metabolism During Treatment of Endometriosis with the Progestin Dienogest
article
OA: closed
CC0
⤵ 17 in-corpus citations
AI-generated summary
Treatment of endometriosis with dienogest for 24 weeks resulted in minor decreases in HDL-cholesterol and triglycerides, a transient increase in LDL-cholesterol, and a slight rise in the LDL/HDL ratio.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The effects of a new progestational compound, dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on lipid metabolism have been studied in 84 otherwise healthy women with laparoscopically proven endometriosis. The women, aged 17 to 45, years were treated with 2 mg dienogest in tablet form daily for 24 weeks. The progestin was highly effective on endometriotic lesions and symptoms, showing an objective endoscopic and a subjective symptomatic improvement in 80% and 83% respectively. Triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol and the LDL-cholesterol/HDL-cholesterol ratio were determined before and after 1, 3 and 6 months use of the progestin. There was a maximum decrease of -5.8% in HDL-cholesterol and of -6.5% in triglycerides after 6 months of therapy vis-à-vis the pretreatment values. The maximum increase in LDL-cholesterol of +5.0% was recorded by the end of the first month of dienogest ingestion. The LDL-cholesterol/HDL-cholesterol ratio rose from 1.6 to 1.8 during the course of therapy. There were no significant changes. The data suggest that 2 mg dienogest has little influence on lipid metabolism and provides also in this respect a suitable approach to the hormonal therapy of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (11)
- Carbohydrate Metabolism during Treatment of Endometriosis with the Progestin Dienogest <sup>*</sup>) via openalex
- Changes of Plasma Lipids and Lipoprotein Levels during Danazol Treatment for Endometriosis via openalex
- Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan. via openalex
- Effects of danazol on plasma lipid and lipoprotein levels in healthy women and in women with endometriosis via openalex
- Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate via openalex
- Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. via openalex
- Lipoproteinveränderungen unter Lynestrenol und Danazol in der hormonellen Behandlung der Endometriose via openalex
- Metabolische Effekte und allgemeine Nebenwirkungen bei Endometriose-behandlung mit einem LHRH-Agonisten via openalex
- Plasma lipoproteins during and after danazol treatment via openalex
- Serum Lipoprotein Changes in Female Rats Treated with Progesterone or Synthetic Gestagens Alone or in Combination with Estradiol. I. Total and Fractionated Cholesterol and Lipoprotein Pattern via openalex
- W2116404316 via openalex
Cited by (17)
- Drug development for adenomyosis based on pathophysiology 2025
- Correlation between lipid metabolism and endometriosis: a meta-analysis 2025
- Long-Term Health Consequences of Endometriosis—Pathways and Mediation by Treatment 2020
- The experience of Visanne use in patients of reproductive age with external genital endometriosis 2016
- Dienogest in the treatment of endometriosis 2014
- Dienogest (DNG) in der Therapie der Endometriose Übersicht zur aktuellen Studienlage 2011
- Dienogest 2010
- Dienogest: an oral progestogen for the treatment of endometriosis 2010
- Ethinylestradiol/Dienogest in Oral Contraception 2010
- Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study 2010
- A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis 2009
- Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells 2007
- The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro 2001
- Dienogest 1998
- Reappraisal of progestins in endometriosis therapy 1998
- Progestins for symptomatic endometriosis: a critical analysis of the evidence 1997
- Changing concepts of medical treatment of endometriosis 1993
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:09:15.954262+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK